(For Research Use Only)

Ovarian cancer is a malignant tumor that poses a serious threat to women's health. It ranks third in the incidence of malignant tumors in the female reproductive system, following cervical cancer and endometrial cancer, but has the highest mortality rate among female reproductive system malignancies. Ovarian cancer is often referred to as the "silent killer" because when symptoms appear and patients seek medical attention, about 70% of cases are already in advanced stages, resulting in low 5-year survival rates.

The most common type of ovarian cancer is epithelial ovarian cancer, accounting for approximately 80% of cases. Epithelial ovarian cancer can be further categorized into serous carcinoma (70-80%), endometrioid carcinoma (10%), clear cell carcinoma (10%), mucinous carcinoma (3%), and other rare types (<5%) based on pathological characteristics. Research has shown that different types of ovarian cancer carry different mutated genes, which can assist in histopathological classification and be used clinically for ovarian cancer risk assessment, optimizing treatment plans, and supporting genetic screening.

Furthermore, there is clinical evidence suggesting that molecular subtyping of ovarian cancer can be linked to individualized treatment, leading to improved patient survival rates. It has become an effective approach to guide ovarian cancer treatment.

Molecular Cancer, 2022, 21(1): 114.

CSCO Guidelines - Molecular Characteristics of Different Subtypes

DETECTION CONTENT 

PRODUCT INFORMATION

DETECTION SIGNIFICANCE 

1.Prognostic Assessment: Ovarian cancer is highly heterogeneous. Accurately classify the tumor tissues and suggest the prognosis of patients according to the molecular characteristics of different tissue subtypes, assisted by morphology and immunohistochemistry.

2. Treatment Guidance: Guide the use of PARP inhibitors to BRCA1 / 2 gene mutation; Guide the use of RAF / MEK inhibitors to BRAF gene mutationin patients with low-grade serous carcinoma; Suggest the use of cross-cancer or clinical trial drugs to other gene mutations.

3. Genetic Risk: Provide a basis for the diagnosis and subsequent diagnosis and treatment of hereditary tumors by detecting whether the proband or high-risk group carries germline mutations such as BRCA1 / 2.

FEATURES & ADVANTAGES

Ease of Use:  Based on the independent patent technology RingCap^®, Library preparation  in  2 steps.

High Sensitivity: Detect gene mutations with an abundance as low as 5% in a 10 ng DNA sample.

Genetic Assessment: Conducting comprehensive exome sequencing and germline sequencing of the BRCA1/2 genes can assess familial genetic risk.

Molecular Subtyping: It aids in personalized precision treatment and improving the prognosis of ovarian cancer patients.

DETECTION PROCESS 

1. Nucleic Acid Extraction

2. Library Preparation （3.5 hours total time）

3. Sequencing

4. Auto-data Analysis

5. Report